September 10-12, 2018
San Diego, CA

2018 Speakers

Expand/Collapse

Brandon Iker
Research Scientist and Clinical Investigator
Amway

Brandon Iker, Ph.D., is a research scientist and clinical investigator at Amway Corporation.  Prior to working at Amway, Dr. Iker completed his graduate and postdoctoral work in the College of Agriculture and Life Sciences at the University of Arizona, where he studied the use of novel high throughput sequencing strategies and molecular detection techniques for the detection, quantification, and identification of microbial contaminants in complex environmental matrices like food, soil, and water.  His current research focus is on the application of microbial ecology and systems biology to better understand the complex interactions between host and microbe. Dr. Iker works with a small team leading Amway’s microbiome research where he helps lead new product development and new technology acquisition and innovation across multiple categories in the business.

Day One

Tuesday, September 11

14.15 | Panel Discussion: Exploring the Benefits/Negatives of 16S Amplicon Sequencing Versus Whole Genome Sequencing for Translational Microbiome Research?

Greg Hillebrand
Senior Principal Scientist
Amway

Greg Hillebrand is a biochemist in Amway’s Research and Development department.  He received his PhD from Baylor College of Medicine and has 32 years of industrial research experience in skin and cosmetic science.  His research focuses on the host and environmental factors that affect the skin function and appearance.

Day Two

Wednesday, September 12

13.40 | Panel Discussion: Creating Long Term Cosmetic Propositions & Communicating the Benefits to Consumers – How to Enter the Cosmetic Market

12.00 | A One-Year Longitudinal Study of the Facial Skin Microbiome

Larry Weiss, MD

AOBiome

Travis Whitfill
Chief Scientific Officer
Azitra Inc.

Travis Whitfill is the Chief Science Officer of Azitra Inc. His background began in molecular biology and biochemistry after receiving scientific training at the MD Anderson Cancer Center and Duke University. He has co-founded several biotech and healthcare startups companies, including Azitra. Mr. Whitfill’s strong background in entrepreneurship and business was recently acknowledged when he was named one of Forbes’ 30 Under 30 in 2018. He serves as a partner at Bios Partners, a healthcare-focused venture capital fund based in Texas, and as the Senior Analyst at Bios Research, which provides research services to institutional investors. He also is an Associate Research Scientist in the Department of Pediatrics at Yale University. Mr. Whitfill received degrees from Yale University (MPH) and Dallas Baptist University (BS in biology).

Day One

Tuesday, September 11

15.15 | Engineered “Bugs as Drugs” for the Skin: A Novel Approach for Skin Therapeutics

Manoj Dadlani
CEO
CosmosID

Day One

Tuesday, September 11

12.15 | Skin Microbiome Characterization: Standards, Sequencing, and Bioinformatics

Lada Rasochova
Founder & CEO
Dermala

Dr. Lada Rasochova is the founder and CEO of Dermala Inc., a human microbiome company developing treatments for chronic skin diseases and conditions. Dr. Rasochova has been involved in commercialization of biotech and pharma products for the past 20 years. She spent 15 years in industry where she held various leadership positions, including as the leader of Vaccine Technologies and director of new business development in Dowpharma, a biotech division of the Dow Chemical Company, Mycogen, a biotech startup (acquired by Dow Chemical), and the CEO of Jadus BioScience, an early stage diagnostic company. Dr. Rasochova is also the managing director of the Rady Venture Fund and serves as the founding executive director of the California Institute for Innovation and Development at UC San Diego, founding director of StartR and mystartupXX accelerators, and on boards of several companies, centers and institutes, including the UC San Diego Center for Drug Discovery Innovation and the Qualcomm Institute.

Day Two

Wednesday, September 12

13.40 | Panel Discussion: Creating Long Term Cosmetic Propositions & Communicating the Benefits to Consumers – How to Enter the Cosmetic Market

12.20 | Developing Microbiome-Based Acne Therapies by the Utilizing Gut Microbiome in Skin Health

Nakissa Sadrieh
Director, Cosmetics Division
FDA

Dr. Sadrieh obtained her doctorate in Toxicology in 1993 from Rutgers University in New Jersey. Following a postdoctoral fellowship in the Laboratory of Chemical Carcinogenesis at the National Cancer Institute, Dr. Sadrieh joined the Food and Drug Administration in 1996 as a pharmacology and toxicology reviewer. In 1998, Dr. Sadrieh became the supervisory pharmacologist in the Division of Medical Imaging and Radiopharmaceutical Drug Products, Center for Drug Evaluation and Research (CDER). In 2002, Dr. Sadrieh joined CDER’s Office of Pharmaceutical Science, as the Associate Director for Research Policy and Implementation. In OPS, Dr. Sadrieh’s work focused on scientific research that directly impacted regulatory decisions. As a scientific advisor to the Office of Pharmaceutical Science (OPS), Dr. Sadrieh supported CDER’s scientific mission, by designing, conducting and managing appropriate research projects aimed at resolving pending regulatory questions. Since 2004, Dr. Sadrieh has assessed the impact of new technologies, such as nanotechnology, on drug development and the regulatory review process, and as such, she is one of the Agency experts in all matters related to Nanotechnology. In October 2013, Dr. Sadrieh Joined the Center for Food Safety and Nutrition (CFSAN), as the Director of the Cosmetics Division, in the Office of Cosmetics and Colors (OCAC).

Day One

Tuesday, September 11

14.30 | Presentation Title to be confirmed

Curtis Huttenhower
Associate Professor, Biostatistics
Harvard TH Chan School of Public Health

Dr. Curtis Huttenhower is an Associate Professor in Biostatistics at the Harvard School of Public Health and an Associate Member at the Broad Institute.  He participated extensively in the NIH Human Microbiome Project and co-leads the "HMP2" Center for Characterizing the gut microbial ecosystem in IBD.  His lab focuses on computational methods for functional analysis of microbial communities.  This includes systems biology reconstructions integrating metagenomic, metatranscriptomic, and other microbial community 'omics, the human microbiome in autoimmune disease such as IBD, and its potential as a diagnostic tool and point of therapeutic intervention.

Day One

Tuesday, September 11

11.45 | Panel Discussion: Where will the Skin Microbiome need Standardization to Advance Science & Future Products?

09.15 | Structure, Function and Diversity of the Healthy Human Microbiome

Julia Oh
Assistant Professor
The Jackson Laboratory

Dr. Oh's main research interests focus on the human microbiome—the diverse bacteria, fungi, and viruses that inhabit our bodies—for its potential to deliver treatments for infectious and other diseases.  Dr. Oh comes to the microbiome world by way of fungal chemogenomics with technologist and geneticist Dr. Ronald Davis at Stanford and comparative genomics of wild wine yeast at the FAS Center for Systems Biology at Harvard. Prior to joining the Jackson Laboratory, she was a postdoctoral fellow at the National Human Genome Research Institute (NHGRI) of the National Institutes of Health.

Day One

Tuesday, September 11

11.45 | Panel Discussion: Where will the Skin Microbiome need Standardization to Advance Science & Future Products?

09.45 | The Human Skin Microbiome: From Metagenomes to Therapeutics

Nathan Archer
Post-Doctoral Fellow
John Hopkins School of Medicine

Day Two

Wednesday, September 12

09.30 | Scratching the Surface: Discovering the Role of the Microbiota in a Mouse Model of Atopic Dermatitis-Like Skin Inflammation

Lionel Breton
L’Oreal Advanced Research, Scientific Director
L’Oreal

Pre-Conference Workshop

Monday, September 10

13.00 | The Gut-Skin-Brain Axis in Health and Disease

Magali Moreau
Associate Principal Scientist, Open Research
L’Oreal

Day Two

Wednesday, September 12

13.40 | Panel Discussion: Creating Long Term Cosmetic Propositions & Communicating the Benefits to Consumers – How to Enter the Cosmetic Market

11.00 | Human Skin Microbiome - Opportunities for Healthy Skin with Aging

Mark Wilson
CEO
Matrisys Bioscience

Day One

Tuesday, September 11

15.35 | Rebalancing the Skin Microbiome and Innate Immune System to Improve Skin Health

Malcolm Kendall
CEO
Microbiome Insights

Malcolm Kendall has over 28 years of operational management, entrepreneurial, venture capital investment and leadership experience, the majority of which has been focused on company creation and building value in technology and biotechnology companies. Before founding Microbiome Insights, he was the co-founder and CEO of Indel Therapeutics Inc., a Vancouver-based biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. Prior to this, Malcolm was an investment professional with life science focused venture capital firms MDS Capital (now Lumira Capital), BioVista Capital (now Hatteras Venture Partners) and Intersouth Partners. Before entering business, he served in the U.S. Army where he honed his leadership skills as an Infantry and Special Forces officer. Malcolm has been an advisor and board member to numerous companies and organizations and is currently a member of the board of directors of Semios BIO Technologies, a mentor for the entrepreneurship@UBC program and an adjunct professor at the MBA MOT program at Simon Fraser University. He received his undergraduate degree from Washington and Lee University and an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina.

Day One

Tuesday, September 11

10.15 | From Swab to Data – Considerations for Designing Skin Microbiome Studies

Emma Taylor
CEO
Naked Biome

Dr. Emma Taylor the CEO and Co-Founder of Naked Biome, Inc.  She is a  UCLA-trained and board-certified Dermatologist and Dermatopathologist and remained at UCLA as an assistant professor of Dermatology and Dermatopathology when she c0-founded Naked Biome. She is also an inventor of 2 published patents,  has published in notable journals such as Nature and the Journal of the American Academy of Dermatology, and is the author on more than 40 book chapters

Day One

Tuesday, September 11

16.15 | Challenges in Microbiome Therapeutic Development

Wynand Alkema
Principal Scientist, Data Science
NIZO

Day One

Tuesday, September 11

13.00 | Predictive Modelling of Host-Microbe Interactions for the Discovery of New Skin Microbiome Modulators

Amanda Nelson
Assistant Professor, Dermatology
PennState

Amanda Nelson, PhD, is an Assistant Professor of Dermatology at the Pennsylvania State University College of Medicine in Hershey, PA.  Dr. Nelson received her graduate degree in Molecular Medicine at the Pennsylvania State University College of Medicine where she studied the mechanism of action of isotretinoin in the treatment of acne vulgaris. Dr. Nelson completed two postdoctoral research fellowships in dermatology at Penn State and at Johns Hopkins University where she expanded her expertise in sebaceous glands, hair follicles, skin stem cells and wound healing.  Her current areas of research interest include acne, hidradenitis suppurativa, innate immunity in non-melanoma skin cancers and the skin microbiome in inflammatory skin disease. Her work is supported by grants from NIH/NIAMS, American Acne and Rosacea Society, Hidradenitis Suppurativa Foundation and the Acne Cure Alliance. Dr. Nelson serves as a reviewer for multiple journals including the Journal of Investigative Dermatology. Dr. Nelson has authored numerous manuscripts and book chapters on the pathogenesis of sebaceous gland, hair follicle and wound-healing and currently holds multiple patents related to her work.

Day One

Tuesday, September 11

11.45 | Panel Discussion: Where will the Skin Microbiome need Standardization to Advance Science & Future Products?

Day Two

Wednesday, September 12

09.00 | Isolation and Identification of the Follicular Microbiome: Insights into Study Design for Acne Research

Yug Varma
CEO
Phi Therapeutics

Yug Varma, PhD is a microbiome researcher at UCSF. Yug obtained his Ph.D. from Johns Hopkins University, and has more than 10 years of research experience with extensive skills in biochemistry and microbiology. He's passionate about bringing to market a proprietary antibacterial platform to tackle major public health concerns.

Day One

Tuesday, September 11

16.55 | Precise Manipulations of the Skin Microbiome: ‘Kill & Replace’ Approach to Disease

Eva Berkes
Co-Founder, Principal & CSO
Quorum Innovations

Dr. Berkes established a private practice in 2002. She is board certified in allergy, asthma and immunology. She graduated from Williams College and attended medical school at the University of Florida, where she remained for her residency in internal medicine. Dr. Berkes completed a fellowship in allergy, asthma and immunology at The Scripps Clinic and Research Institute. Her research focuses on the human microbiome and its relationships with human innate immunity, biofilms and disease states associated with chronic and allergic inflammation. Dr. Berkes is also a co-founder of the Hawthorne Clinic.

Day Two

Wednesday, September 12

13.40 | Panel Discussion: Creating Long Term Cosmetic Propositions & Communicating the Benefits to Consumers – How to Enter the Cosmetic Market

Stephen France
Business Development
SkinBioTherapeutics

Stephen has spent the last 15 years involved in the biotechnology and healthcare sectors with a focus on highly disruptive technology emerging from academic institutions. Stephen has been supported over 20 venture-backed businesses and has been involved in the translation of a number of technology concepts from the laboratory bench, through clinical development and on to commercialization.   Stephen has a Ph.D. in molecular cancer biology and has worked in academia (USA, UK) and the pharmaceutical industry with AstraZeneca PLC.

Huiying Li
Associate Professor, Molecular & Medical Pharmacology
UCLA

Dr. Huiying Li is an Associate Professor in the Department of Molecular and Medical Pharmacology at UCLA School of Medicine.  Her research group investigates the role of the skin microbiome in health and disease, including two most common skin diseases, acne vulgaris and atopic dermatitis.  By combining high-throughput technologies, bioinformatics, microbiology, and biochemistry, Dr. Li and her group analyze the genomes, metagenomes, metatranscriptomes, and metabolomes of the microorganisms in the human microbiome and their interactions with the host.  The findings from these studies can potentially lead to new diagnostics and interventions.

Day One

Tuesday, September 11

14.15 | Panel Discussion: Exploring the Benefits/Negatives of 16S Amplicon Sequencing Versus Whole Genome Sequencing for Translational Microbiome Research?

12.30 | The Human Skin Microbiome in Health and Disease

Livia Zaramela
Postdoctoral fellow, Zengler lab
UCSD

As a postdoctoral fellow at the Zengler lab, Livia's primary research interests are to understand how the interaction amongst the microorganisms, the host, and the environment define complex ecosystems. In particular, Livia has a special interest in applying system biology approaches to identify the components causing major shifts in the skin and gut microbiome under perturbation, such as inflammatory diseases and diet. Before starting her postdoctoral positions at UCSD, Livia received her PhD in Molecular Biology & Bioinformatics at the University of Sao Paulo.

Day One

Tuesday, September 11

10.00 | The Role of the Active Microbiome in Skin Diseases

Pieter Dorrestein
Professor, Skaggs School of Pharmacy & Pharmaceutical Sciences
UCSD

The Dorrestein lab aims to develop new mass spectrometry based methods to understand the chemistry of microbes, our microbiome and their ecological niche. In short, we develop tools that translate the chemical language between cells. This research requires the understanding of (microbial) genomics, proteomics, imaging mass spectrometry, genome mining, enzymology, small molecules structure elucidation, bioactivity screening, antibiotic resistance and an understanding of small molecule structure elucidation methods. The collaborative mass spectrometry innovation center that he directs is well equipped and now has twelve mass spectrometers, that are used in the studies to investigate capture cellular chatter (e.g. metabolic exchange), metabolomics, metabolism and to develop methods to characterize natural products. These tools are used to defining the spatial distribution of natural products in 2D, 3D and in some cases real-time. Areas of recent research directions are capturing mass spectrometry knowledge to understand the microbiome, non invasive drug metabolism monitoring, informatics of metabolomics, microbe-microbe, microbe-immune cells, microbe-host, stem cell-cancer cell interactions and diseased vs. non-disease model organisms and the development of strategies for mass spectrometry based genome mining and to detect and structurally characterize metabolites through crowd source annotation of molecular information on the Global Natural Products Social Molecular Networking through the NIH supported center for computational mass spectrometry that is co-developed with Nuno Bandeira. A more detailed biography can be found in Nature

Day One

Tuesday, September 11

14.45 | Microbial Metabolites of the Skin Microbiome - Identifying Skin Chemistry to Search for Function

Richard Gallo, MD, PhD
Distinguished Professor and Founding Chair, Department of Dermatology
UCSD

The Gallo laboratory focuses on understanding mechanisms of innate defense of the skin, demonstrating the cooperation of genes encoded by both host and microbiome. Critical past discoveries include finding that the mammalian skin makes antimicrobial peptides, and a ten year history of defining critical functions for specific bacteria as they interact with the human innate immune system. Gene targeting and molecular analysis has demonstrated how antimicrobial peptides are critical to mammalian immunity and contribute to human diseases such as acne, rosacea and psoriasis. As direct extension of this work, the Gallo lab has experimentally demonstrated that the normal community of bacteria on human skin contains strain-specific genes that further help limit skin inflammation and protect against infection. A precise molecular characterization of these events has led to successful human clinical trials and continues to uncover novel functions for the skin microbiome in human diseases.

Day One

Tuesday, September 11

08.30 | Targeted Design of Microbial Biotherapy for Skin Disease

Jason Harcup
Global VP, Personal Care Research & Prestige Division
Unilever

Dr. Jason Harcup is Global Vice President for Personal Care Research, responsible for Unilever’s worldwide research program across its €20 Billion Personal Care businesses in Skin Care and Cleansing, Hair and Scalp, Deodorants, Oral Care and also delivering to the Prestige Division. He has ultimate responsibility for several hundred mostly PhD level scientists located in 5 laboratories across the USA, Europe, India and China. He is located in Unilever’s UK research hub.

Day Two

Wednesday, September 12

13.40 | Panel Discussion: Creating Long Term Cosmetic Propositions & Communicating the Benefits to Consumers – How to Enter the Cosmetic Market

11.20 | Commercializing Microbiome-based Personal Care Products

Thomas Hitchcock
CEO
Xycrobe Therapeutics

Thomas Hitchcock is the founder and CEO of Xycrobe Therapeutics. An entrepreneur in the biotech space, Thomas has been instrumental in bringing several medical technologies successfully to the dermatological and aesthetics markets.  Thomas holds a doctorate in molecular genetics from Clemson University where he did his research on DNA damage and repair.

Day One

Tuesday, September 11

16.35 | Using Synthetic Biology To Develop Microbiome-Based Skin Therapetics